HBM Holdings-B (02142) surged nearly 5%, reaching HK$13.62 by the time of writing, with a trading volume of HK$15.42 million. The uptick follows an announcement on November 24, where the company disclosed that its indirect wholly-owned subsidiary, HBM (Shanghai), has amended and expanded its collaboration agreement with AstraZeneca PLC (AZN). The revised agreement broadens the scope of their partnership to jointly discover and develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers. The financial terms remain consistent with the framework established in the original agreement.